Stoke Therapeutics, Inc. (STOK)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $1.83B
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Latest financial period: June 30, 2026
Filed with the SEC: August 3, 2026
Estimated earnings date: November 3, 2026
Profit #1380 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 5.2% | 7.3% | 9.3% | 14.6% |
Growth #1483 of 1484 companies
Payout #1117 of 1484 companies
Safety #661 of 1484 companies
Price #1456 of 1484 companies
